Lupin Share Price
(LUPIN)
Check the latest share price of Lupin, details on performance, fundamentals, analyst ratings, peer comparison, financials, company news, analysis, and shareholding pattern for informed investing decisions.
as on 04:01PM, 12 May 2025
NSE
Lupin Performance
Get real-time share price information, day’s high and low, historical returns and market stats.
Day's Low
Day's High
₹1,974Day's Price Range₹2,04552 Week's Low
52 Week's High
₹1,493.352-Week Price Range₹2,402.9
| Returns % | |
| 1 Month Return | + 1.22 % |
| 3 Month Return | + 0.6 % |
| 1 Year Return | + 20.66 % |
| 3 Year Return | + 193.51 % |
| 5 Year Return | + 139.17 % |
| Market Stats | |
| Previous Close | ₹2,037.40 |
| Open | ₹1,998.00 |
| Volume | 12.08L |
| Upper Circuit | ₹2,241.10 |
| Lower Circuit | ₹1,833.70 |
Lupin Fundamentals & Key Indicators
Check the fundamental ratios and key indicators of the company like P/E, P/B, PEG, Dividend yield etc.
Market Cap
₹93,031.05 Cr
Return on Equity (ROE)
11.92
PE Ratio (TTM)
32.38
Return on capital employed (ROCE)
13.96
Industry PE ratio
53.76
Beta (LTM)
0.68
P/B Ratio
3.58
Dividend Yield
0.49
PEG Ratio
1.37
Quarterly Earnings Growth YOY
38.82
EPS (TTM)
42.47
Sector
Pharmaceuticals
Book Value
313.59
Technical Analysis
Bullish
View Technical Analysis
How to invest in Lupin
Investing in Lupin is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Lupin or LUPIN on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Lupin or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Lupin with just a few clicks!
Lupin Stock's Interest Amongst Investors
Lupin Valuation
Track how the P/E of Lupin has moved over time to understand valuation trends.
Lupin in the last 5 years
Lowest (-6437.86x)
December 3, 2018
Today (32.38x)
May 9, 2025
Industry (53.76x)
May 9, 2025
Highest (517.33x)
December 2, 2022
Today’s Price to Earnings Ratio: 32.38x
Analysts Recommendation on Lupin
Get updated buy, sell, and hold recommendations by analysts on Lupin.
based on 36 analysts
58.33%
Buy
30.56%
Hold
11.11%
Sell
58.33% of analysts recommend a 'BUY' rating for Lupin. Average target price of ₹2272.5
Source: S&P Global Market Intelligence
Analysts Forecast on Lupin
Get share price movements and forecasts by analysts on Lupin.
Lupin price forecast by 36 analysts
Upside of11.54%
High
₹2626
Target
₹2272.50
Low
₹1900
Lupin target price ₹2272.5, a slight upside of 11.54% compared to current price of ₹2039.8. According to 36 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Lupin revenue growth forecast
Expected growth rate Q1, FY2027:34.76%
Forecast
Actual
Including amortisation and stock based compensations
Lupin EPS growth forecast
EPS estimate Q1, FY2027:111.57%
Forecast
Actual
Source: S&P Global Market Intelligence
Lupin Financials
Get the annual and quarterly financial summary of Lupin, including revenue, profit, loss and more.
Lupin Index Inclusions
Lupin Earnings and Dividends
View detailed summary of the earnings and dividend history of Lupin.
Lupin Ltd Earnings Results
Lupin Ltd’s net profit jumped 39.48% since last year same period to ₹855.16Cr in the Q3 2024-2025. On a quarterly growth basis, Lupin Ltd has generated 0.3% jump in its net profits since last 3-months.
Read More about Earnings ResultsLupin Ltd Dividends May,2024
In the quarter ending March 2024, Lupin Ltd has declared dividend of ₹8 - translating a dividend yield of 0.59%.
Read More about Dividends
Lupin Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Lupin.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.92% | 0.00 | |
| Foreign Institutions | 21.46% | 0.00 | |
| Mutual Funds | 17.55% | 0.00 | |
| Retail Investors | 6.2% | 0.00 | |
| Others | 7.87% | 0.00 |
Lupin vs Peers
Compare market cap, revenue, PE, and other key metrics of Lupin with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 93,031.05 | 27.83% | 0.51 | 1,935 | 20,010 | |
| BUY | 13,416.13 | -5.4% | 0.52 | 413 | 2,013 | |
| BUY | 68,226.69 | 13.71% | 0.56 | 3,168 | 29,001 | |
| HOLD | 88,412.75 | 34.29% | 0.64 | 3,854 | 19,547 | |
| BUY | 64,100.63 | 13.36% | 0.53 | NA | NA |
Lupin News & Key Events
Latest news and events at one place to help you take investing decisions in Lupin.
Lupin Shares Drop Due to US Policy Concerns - 12 May, 2025
Lupin shares fell by 2.09% to Rs 1995.70, influenced by renewed concerns over US drug manufacturing policies, affecting the broader pharma sector.Lupin Receives USFDA Approval for Raltegravir - 09 May, 2025
Lupin Ltd has received approval from the USFDA for its Raltegravir tablets, allowing it to benefit from 180 days of exclusivity. This approval enhances Lupin's generics portfolio, particularly in the HIV treatment market.Lupin Launches Generic Seizure Drug in US - 07 May, 2025
Lupin Limited has launched Eslicarbazepine Acetate tablets in the US, following FDA approval. The drug is indicated for partial-onset seizures and offers significant market potential with estimated annual sales of $395 million for the reference drug, Aptiom. Lupin is among the first ANDA applicants, securing 180 days of shared generic exclusivity, which could contribute $150-200 million to FY26 revenue.Nomura Maintains Buy Call on Lupin Ltd - 02 May, 2025
Nomura has a Buy rating on Lupin Ltd, noting an increase in gSpiriva market share to 34%. The company also launched gPredForte, boosting its market share to 17%.Lupin Updates Timeline for Business Transfers - 30 Apr, 2025
Lupin Limited has announced a revised timeline for transferring its API R&D division and OTC Consumer Healthcare business to subsidiaries, now expected by June 30, 2025. This strategic move aims to streamline operations and enhance focus on core areas.Lupin Reduces Price of Key TB Drug by 25% - 25 Apr, 2025
Lupin Limited has successfully reduced the price of the tuberculosis drug pretomanid by 25%, making it available for $169 per treatment course through the Global Drug Facility. This price cut enhances global access to essential TB medicine.Lupin Secures USFDA Approval for Tolvaptan Tablets - 24 Apr, 2025
Lupin Ltd has received USFDA approval for its generic Tolvaptan tablets, granting it 180 days of exclusivity. This marks a significant entry into the nephrology market, with estimated annual sales of $1.47 billion. The product will be manufactured at Lupin's Nagpur facility and is expected to launch soon, enhancing Lupin's market position and revenue potential.Lupin's Strategic Moves and Market Developments - 23 Apr, 2025
Lupin Ltd is making significant strides with the launch of gTolvaptan in the US, gaining market sentiment, while facing challenges from patent rulings and product recalls. The company also enhances its cloud infrastructure and receives NABL accreditation for diagnostics labs.Lupin Pharmaceuticals Recalls Antidepressant Medication - 22 Apr, 2025
Lupin Pharmaceuticals Inc, a subsidiary of Lupin Ltd, is recalling 2,724 bottles of clomiPRAMINE hydrochloride capsules due to failed impurity specifications, marking a Class II recall initiated on April 18.Lupin Faces Patent Challenges but Maintains Growth - 17 Apr, 2025
Lupin Ltd faces a patent ruling in favor of Astellas Pharma regarding Myrbetriq, with a trial set for 2026. Despite this, Lupin's financials remain strong, with a significant profit increase and positive ratings from brokerages. The company received regulatory approval for its Nagpur facility, indicating ongoing operational compliance.Lupin Faces Setback in Myrbetriq Patent Case - 16 Apr, 2025
Lupin Ltd shares dropped significantly after a US court ruled against them in a patent case involving Myrbetriq, blocking their market access and potentially leading to financial penalties. The ruling is expected to impact future revenue forecasts negatively.
Insights on Lupin Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 4 quarters, 359.43 Cr → 855.16 Cr (in ₹), with an average increase of 20.5% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 4.99K Cr → 5.82K Cr (in ₹), with an average increase of 4.9% per quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, LUPIN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Price Rise
In the last 1 month, LUPIN stock has moved up by 1.2%
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 16.92% to 17.55% in Mar 2025 quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 54.1% return, outperforming this stock by 33.4%
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 22.04% to 21.46% in Mar 2025 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 6.26% to 6.20% in Mar 2025 quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 46.95% to 46.92% in Mar 2025 quarter
About Lupin
The company's top products include a wide range of prescription and over-the-counter drugs, including antibiotics, cardiovascular medications, antidiabetics, and anti-asthmatics. Lupin Ltd also manufactures and markets a variety of branded products, including Metoject, Lupitac, and Lupizole. In addition, the company produces a number of popular generic drugs, such as Amlodipine, Montelukast, and Cetirizine.
Lupin Ltd is one of the world's leading manufacturers of APIs, with a portfolio that includes more than 200 APIs and intermediates. The company also produces a range of animal health products, such as veterinary vaccines, feed supplements, and pet care products.
Revenue: ₹5,618.56Cr as on December 2024 (Q4 24)
Net Profit: ₹858.86Cr as on December 2024 (Q4 24)
Listing date: 30 Nov, 1994
Chairperson Name: M D Gupta
| Organisation | Lupin Ltd |
| Industry | Pharmaceuticals |
| CEO | M D Gupta |
| E-voting on shares | Click here to vote |
Indian Mutual Funds that own Lupin
Check out the Mutual Funds with significant holdings in Lupin.
FAQs
What is Lupin Ltd price today?
Lupin Ltd share price today stands at ₹2039.8, Open: ₹1998, Previous Close: ₹2037.4, High: ₹2045, Low: ₹1974, 52 Week High: ₹2402.9, 52 Week Low: ₹1493.3.
How to Buy Lupin Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Lupin Ltd shares
What are today's traded volumes of Lupin Ltd?
Today's traded volume of Lupin Ltd(LUPIN) is 12.08L.
What is today's market capitalisation of Lupin Ltd?
Today's market capitalisation of Lupin Ltd(LUPIN) is ₹93,031.05 Cr.
What is the 52 Week High and Low Range of Lupin Ltd?
How much percentage Lupin Ltd is down from its 52 Week High?
Lupin Ltd (LUPIN) share price is ₹2039.8. It is down -15.11% from its 52 Week High price of ₹2402.9
How much percentage Lupin Ltd is up from its 52 Week low?
Lupin Ltd (LUPIN) share price is ₹2039.8. It is up 36.60% from its 52 Week Low price of ₹1493.3